MedTrace Logo

A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator

NCT00760578 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2013-05-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if MSDC-0160 is effective in the treatment of Type 2 diabetes.

Conditions

Interventions

DRUG

Placebo

Once daily, oral

DRUG

Pioglitazone

Once daily, oral

DRUG

MSDC-0160 90 mg

Once daily, oral

DRUG

MSDC-0160 220 mg

Once daily, oral

Sponsors & Collaborators

  • Metabolic Solutions Development Company

    lead INDUSTRY

Principal Investigators

  • Jerry R Colca, PhD · Metabolic Solutions Development Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-01-31
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00760578 on ClinicalTrials.gov